HOME >> BIOLOGY >> NEWS
The future of HIV therapeutics is brightening, according to Gladstone Institutes Director

Recent discoveries about the way that HIV infects cells are propelling the development of a broad spectrum of promising new antiviral drugs, according to an invited commentary on the topic in the current issue of Nature Immunology (August 27, 2004).

The assessment is made by Gladstone Institute of Virology and Immunology (GIVI) Director Warner Greene, MD, PhD, who also serves as professor of medicine, microbiology and immunology at the University of California, San Francisco.

In the piece, Greene points out that basic research on HIV, a relatively simple pathogen with only nine genes encoding 15 proteins, are leading to compelling new therapies that deny the initial entry of HIV into its cellular host. In addition, fast-moving research of naturally occurring factors with potent antiviral properties is opening the way for future development of an entirely new class of anti-HIV drugs.

New agents that block the first step in HIV's life cycle, the entry of the HIV virion (a single virus particle) into host CD4 T-cells, are quickly moving down the drug development pipeline. Chief among these therapeutics are drugs known as chemokine receptor antagonists that interfere with HIV's ability to bind to CCR5, one of two key surface receptors needed for the virus to penetrate the cell. Although these HIV co-receptors were identified only seven years ago, basic studies performed by both GIVI investigators and scientists around the world have helped accelerate clinical development of CCR5 antagonists as a new class of anti-HIV drugs. Several major pharmaceutical companies are now racing to the finishing line.

These advances address but one of the three steps required for successful entry of the HIV virus. The other two steps involve the attachment of HIV virions to surface CD4 receptors and the final fusion of virions to target cells. These steps are also being targeted with new antiviral drugs. Combinations of inhibitors acting at each o
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-695-3833
University of California - San Francisco
27-Aug-2004


Page: 1 2 3

Related biology news :

1. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
2. Charting the future in prostate cancer care: A call to action
3. Sandia experiments may reduce possibility of future water wars
4. Will a reduction in military spending improve our environmental future?
5. Engineering endurance: The future of the Olympics?
6. The future of nanotechnology
7. Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
8. Endometriosis: Could angiostatic therapy be the new treatment of the future?
9. Plants for the future: A European vision for plant biotechnology towards 2025
10. Plant pathologists to discuss the future of organic farming
11. Stem cells commit to a future of fat with one signal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) ... oral peptide drug candidates, PTG-100 and PTG-200, at ... Crohn,s and Colitis Organization (ECCO).  The ECCO congress ... from February 15 – 18, 2017. ... on Protagonist drug candidates PTG-100 and PTG-200. PTG-100, ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
Cached News: